UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): December 10, 2014

 

bluebird bio, Inc.

(Exact name of registrant as specified in its charter)

 

 

DELAWARE

 

001-35966

 

13-3680878

(State or other jurisdiction of
incorporation)

 

(Commission File Number)

 

(I.R.S. Employer
Identification No.)

 

150 Second Street Cambridge, MA

 

02141

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code (339) 499-9300

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 

 

 

 

Item 7.01

Regulation FD Disclosure

 

On December 10, 2014, bluebird bio, Inc. (“bluebird”) conducted an investor webcast summarizing clinical data from its Northstar (HGB-204) and HGB-205 clinical trials of its LentiGlobin product candidate presented at the 56th Annual Meeting of the American Society of Hematology in San Francisco, CA on December 8, 2014.  A copy of the presentation is being furnished as Exhibit 99.1 to this Report on Form 8-K.

The information in Item 7.01 of this Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing

Report on Form 8-K and is incorporated herein by reference.

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit No.

 

Description

 

99.1

 

Investor presentation provided by bluebird bio, Inc. on December 10, 2014.

 

 

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: December 10, 2014

 

 

 

bluebird bio, Inc.

 

 

 

By:

 

/s/ Jason F. Cole

 

 

 

 

Jason Cole

 

 

 

 

Senior Vice President, General Counsel

 

 

 

 

 

EXHIBIT INDEX

 

Exhibit No.

 

Description

 

99.1

 

Investor presentation provided by bluebird bio, Inc. on December 10, 2014.